A phase 1b, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).

  • Flemming, Shaun (Primary Chief Investigator (PCI))
  • Wei, Andrew (Chief Investigator (CI))
  • Kennedy, Nola (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date23/05/19 → 31/12/26

Keywords

  • Malignant Haematology
  • Acute Myeloid Leukaemia (AML)
  • Myelodysplastic syndrome
  • Clinical trial